ArticleCureus2026
Compound Heterozygous Sickle Cell-Beta Thalassemia Presenting As Chronic Hemolytic Anemia With Microcytosis and Prominent Left Ventricular Trabeculation: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sickle cell-beta thalassemia, a compound heterozygous hemoglobinopathy, can be difficult to diagnose because clinical features and laboratory findings often overlap with other hematological disorders. We report a 26-year-old man from Assam who presented with eight days of progressive jaundice. Further evaluation revealed chronic hemolysis that had gone undiagnosed for years. He also reported one week of abdominal distension and generalized weakness. Clinical examination revealed pallor, icterus, and moderate splenomegaly. Laboratory evaluation demonstrated anemia (hemoglobin 6.3-7.9 g/dL), microcytosis, elevated lactate dehydrogenase, indirect hyperbilirubinemia, low serum haptoglobin, moderate splenomegaly and reticulocytosis, consistent with ongoing hemolysis. The direct Coombs test was negative, ruling out immune-mediated hemolysis. Infectious causes, including chronic malaria, were excluded, and serological tests for HIV, hepatitis B, and hepatitis C were negative. Blood and urine cultures showed no growth. Glucose-6-phosphate dehydrogenase (G6PD) levels and iron studies were within normal limits, excluding enzymopathy and iron deficiency. Hemoglobin analysis revealed hemoglobin S (HbS) 73.1%, fetal hemoglobin (HbF) 15%, hemoglobin A2 (HbA2) 6.3%, and reduced hemoglobin A (HbA), consistent with compound heterozygous sickle cell-beta thalassemia. Echocardiography demonstrated prominent left ventricular apical trabeculations, likely representing adaptive cardiac remodeling in response to a chronic high-output state. This case illustrates how systematic workup can identify compound hemoglobinopathies in patients with atypical presentations. The finding of HbS-β thalassemia in a patient from Assam is epidemiologically significant, as this compound hemoglobinopathy is extremely rare in this region, where HbE variants predominate. The cardiac findings might reflect cardiovascular changes from chronic, untreated anemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.